WHO ICTRP trial
A multicentre randomised double-blind placebo-controlled study comparing two…
ISRCTN48638981 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN48638981 |
|---|---|
| Public title | A multicentre randomised double-blind placebo-controlled study comparing two regimens of combination induction therapy in early disease-modifying anti-rheumatic drug naïve rheumatoid arthritis |
| Scientific title | A multicentre randomised double-blind placebo-controlled study comparing two regimens of combination induction therapy in early disease-modifying anti-rheumatic drug naïve rheumatoid arthritis |
| Primary sponsor | University of Leeds (UK) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | United Kingdom |
| Conditions | Early rheumatoid arthritis Musculoskeletal Diseases Arthropathies |
| Interventions | Infliximab arm: 1. Methotrexate (10 mg, increasing to 20 mg by six weeks) orally once a week for the treatment period of the trial (18 months) 2. Infliximab (3 mg/kg) intravenous (IV) infusion at baseline, week two, week six and then… |
| Registration date | Apr 30, 2007 |
| Target size | 112 |
| Secondary IDs | RR05/7092 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: